- Update to our [FDA-Approved Oncology Therapies](https://www.oncokb.org/oncology-therapies) page

**Updated Therapeutic Implications**

- Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)

| Level | Gene  | Mutation            | Cancer Type                | Level-Associated Drug(s) in OncoKB™               | Drug(s) Added to OncoKB™             | Evidence                                                                                                                                                                                                                                                                          |
| :---- | :---- | :------------------ | :------------------------- | :------------------------------------------------ | :----------------------------------- | :-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| 1     | ROS1  | Fusions             | Non-Small Cell Lung Cancer | Crizotinib, Entrectinib, Repotrectinib (Level 1\) | Taletrectinib (Level 1\)             | [FDA approval of taletrectinib](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-taletrectinib-ros1-positive-non-small-cell-lung-cancer?utm_medium=email&utm_source=govdelivery);<br/><br/>PMID: [40179330](https://pubmed.ncbi.nlm.nih.gov/40179330/) |
| 1     | ERBB2 | Oncogenic Mutations | Non-Small Cell Lung Cancer | Trastuzumab Deruxtecan (Level 1\)                 | Sevabertinib, Zongertinib (Level 3A) | Abstract: [Loong, HH. et al., ASCO 2025](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.8504);<br/><br/>PMID: [40293180](https://pubmed.ncbi.nlm.nih.gov/40293180/)                                                                                                        |

- Addition of 3 new genes:
  - ASCL1
  - ATMIN
  - DLL3
